Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: Review of evidence

Expert Review of Respiratory Medicine

Volumn 8, Issue 3, 2014, Pages 349-356

  Aggarwal, Bhumika ^a   Gogtay, Jaideep ^a  

^a CIPLA LTD   (India)

Author keywords

chronic obstructive pulmonary disease; inhalation; pressurized metered dose; pressurized metered dose inhaler; spacers

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE; SCOPOLAMINE DERIVATIVE;

AIRWAY CONDUCTANCE; ASTHMA; BREATH ACTUATED INHALER; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DRY POWDER INHALER; FORCED VITAL CAPACITY; HUMAN; INHALATION; INHALATION SPACER; INHALER; LUNG FUNCTION; METERED DOSE INHALER; NEBULIZATION; NEBULIZER; PATIENT CARE; PEAK EXPIRATORY FLOW; PEAK INSPIRATORY FLOW; PRESSURIZED METERED DOSE INHALER; REVIEW; SOFT MIST INHALER; SYSTEMATIC REVIEW; TREATMENT DURATION; EQUIPMENT DESIGN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

BRONCHODILATOR AGENTS; BUDESONIDE; CHOLINERGIC ANTAGONISTS; EQUIPMENT DESIGN; ETHANOLAMINES; HUMANS; METERED DOSE INHALERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84901014639     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.905916     Document Type: Review

References (39)

1. Montuschi P. Drugs for chronic obstructive pulmonary disease. Curr Med Chem 2013; 20(12):1461-3
2. Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2006;1(4): 409-23
3. Fuso L, Mores N, Valente S, et al. Longacting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem 2013;20(12):1477-95
4. Plaza V, Sanchis J. Medical personnel and patient skill in the use of metered dose inhalers: a multicentric study. CESEA Group. Respiration 1998;65(3):195-8
5. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008; 102(4):593-604
6. Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008;75(1):18-25.
7. Rees J. Methods of delivering drugs. BMJ 2005;331(7515):504-6
8. Brennan VK, Osman LM, Graham H, et al. True device compliance: the need to consider both competence and contrivance. Respir Med 2005;99(1):97-102
9. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001; 5(26):1-149
10. Vincken W, Dekhuijzen PNR, Barnes P. ADMIT Group. The ADMIT series - issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J 2010;19(1): 10-20
11. Al-Showair AM, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med 2008;75(1):18-25.
12. Barry PW, O'Callaghan C. Inhalational drug delivery from 7 different spacer devices. Thorax 1996;51(8):835-40
13. Dekhuijzen PNR, Vincken W, Virchow JC, et al. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach. Respir Med 2013; 107(12):1817-21
14. Ram FS, Brocklebank DM, Muers M, et al. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002(1):CD002170
15. Ramlal SK, Visser FJ, Hop WC, et al. The effect of bronchodilators administered via aerochamber or a nebulizer on inspiratory lung function parameters. Respir Med 2013; 107(9): 1393-9
16. Sheth K, Wasserman RL, Lincourt WR, et al. Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: performance and patient satisfaction. Int J Clin Pract 2006;60(10):1218-24
17. Wasserman RL, Sheth K, Lincourt WR, et al. Real-world assessment of a metered-dose inhaler with integrated dose counter. Allergy Asthma Proc 2006;27(6): 486-92
18. Eiser NM, Phillips C, Wooler PA. Does the mode of inhalation affect the bronchodilator response in patients with severe COPD? Respir Med 2001;95(6):476-83.
19. Turner JR, Corkery KJ, Eckman D, et al. Equivalence of continuous flow nebulizer and metered-dose inhaler with reservoir bag for treatment of acute airflow obstruction. Chest 1988;93(3):476-81
20. Woods JA, Usery JB, Self TH, Finch CK. An evaluation of inhaled bronchodilator therapy in patients hospitalized for non-life-threatening COPD exacerbations. South Med J 2011;104(11):742-5
21. Guss D, Barash IA, Castillo EM. Characteristics of spacer device use by patients with asthma and COPD. J Emerg Med 2008;35(4):357-61
22. Tronde A, Gillen M, Borgström L, et al. Pharmacokinetics of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma and COPD. J Clin Pharmacol 2008;48(11):1300-8
23. Kosoglou T, Hubbell J, Xuan F, et al. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary. Int J Chron Obstruct Pulmon Dis 2013;8:107-16
24. Brusasco V, Canonica GW, Dal Negro R, et al. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD. J Aerosol Med Pulm Drug Deliv 2011;24(5):235-43
25. Brashier B, Dhembare P, Jantikar A, et al. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD. Respir Med 2007;101(12): 2464-71
26. Terzano C, Petroianni A, Ricci A, Allegra L. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters. Eur Rev Med Pharmacol Sci 2005;9(4):209-15
27. Koser A, Westerman J, Sharma S, et al. Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. Open Respir Med J 2010;4:86-91
28. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008;68(14):1975-2000
29. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009;69(5):549-65
30. Lyseng-Williamson KA. Budesonide/formoterol pressurized metered-dose inhaler: in chronic obstructive pulmonary disease. Drugs 2009;69(11):1459-70
31. Celli BR, Tashkin DP, Rennard SI, et al. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respir Med 2011;105(8):1176-88
32. Sharafkhaneh A, Southard JG, Goldman M, et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012;106(2):257-68
33. Tashkin DP. Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD. Expert Rev Respir Med 2010;4(6):703-14
34. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis 2012;7: 73-86
35. Doherty DE, Tashkin DP, Kerwin E, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis 2012;7:57-71
36. Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing 2007;36(2): 213-18.
37. Molimard M. How to achieve good compliance and adherence with inhalation therapy. Curr Med Res Opin 2005;21(4): S38-7
38. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. ACCP/ACAAI special report. Chest 2005;127(1): 335-71
39. Montuschi P. Toward a personalized pharmacotherapy of respiratory diseases. Front Pharmacol 2010;1:131